Silence Therapeutics welcomes treatment trial progress at Quark Pharmaceuticals
StockMarketWire.com - Silence Therapeutics welcomed news that Quark Pharmaceuticals had dosed its first patient in a third-phase clinical trial of a treatment for acute kidney injury following cardiac surgery.
Quark held a license to Silence's chemical modification technology and Silence was eligible to receive payments from Quark.
The payments were either 1.5%-4% royalties from Quark plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.
At 9:52am: (LON:SLN) Silence Therapeutics PLC share price was 0p at 156p
Story provided by StockMarketWire.com